The Latest Breaking News from FDA

Google Pixel Watch 3 vs. Samsung Galaxy Watch 7: Which Android smartwatch should you get? We have answers.

The pain and complications of shingles do not end with the episode, as a new study suggests that its impact could be long-term.

There's now an option to treat anaphylaxis via a nasal spray, rather than with an auto-injected medication.

Plus: A listener asks the editors about tariffs and subsidies in the manufacture of electric vehicles.

Blue-chip dividend stocks are of well-established companies offering steady income and financial stability. They are ideal for securing a resilient retirement portfolio, combining consistent dividends with potential capital appreciation. Thus, quality blue-chip dividend stocks Johnson & Johnson (JNJ), Coca-Cola (KO), and McDonald’s (MCD) could be ideal portfolio additions for retirement…

The FDA, which approved the protocols for the studies it now questions, is asking for an additional Phase 3 clinical trial, which would take years and millions of dollars.

Ascendis Pharma stock zoomed higher Monday — closing in on a breakout — after the FDA signed off on its embattled hypoparathyroid disease drug.

The Food and Drug Administration declined to approve MDMA as the first psychedelic drug used to treat post-traumatic stress disorder.

The new treatment, a needle-free alternative, could be used for managing severe allergic responses in children and adults, weighing at least 66 pounds, the FDA said.